Conversely, as both NFκB and BCL-2 drive critical survival mechanisms in NHL, simultaneously targeting both pathways may be beneficial independently of the relationship between NFκB and BCL-2. This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.